Performance evaluation of the small-animal PET scanner ClairvivoPET using NEMA NU 4-2008 Standards.

The aim of this study was to evaluate the performance of ClairvivoPET using NEMA NU4 standards. The ClairvivoPET incorporates a LYSO dual depth-of-interaction detector system with 151 mm axial field of view (FOV). Spatial resolution, sensitivity, counting rate capabilities, and image quality were evaluated using NEMA NU4-2008 standards. Normal mouse imaging was also performed for 10 min after intravenous injection of (18)F(-)-NaF. Data were compared with 19 other preclinical PET scanners. Spatial resolution measured using full width at half maximum on FBP-ramp reconstructed images was 2.16 mm at radial offset 5 mm of the axial centre FOV. The maximum absolute sensitivity for a point source at the FOV centre was 8.72%. Peak noise equivalent counting rate (NECR) was 415 kcps at 14.6 MBq ml(-1). The uniformity with the image-quality phantom was 4.62%. Spillover ratios in the images of air and water filled chambers were 0.19 and 0.06, respectively. Our results were comparable with the 19 other preclinical PET scanners based on NEMA NU4 standards, with excellent sensitivity because of the large FOV. The ClairvivoPET with iterative reconstruction algorithm also provided sufficient visualization of the mouse spine. The high sensitivity and resolution of the ClairvivoPET scanner provided high quality images for preclinical studies.

Wavelet-based resolution recovery using an anatomical prior provides quantitative recovery for human population phantom PET [¹¹C]raclopride data.

The objective of this study was to evaluate a resolution recovery (RR) method using a variety of simulated human brain [¹¹C]raclopride positron emission tomography (PET) images. Simulated datasets of 15 numerical human phantoms were processed by a wavelet-based RR method using an anatomical prior. The anatomical prior was in the form of a hybrid segmented atlas, which combined an atlas for anatomical labelling and a PET image for functional labelling of each anatomical structure. We applied RR to both 60 min static and dynamic PET images. Recovery was quantified in 84 regions, comparing the typical 'true' value for the simulation, as obtained in normal subjects, simulated and RR PET images. The radioactivity concentration in the white matter, striatum and other cortical regions was successfully recovered for the 60 min static image of all 15 human phantoms; the dependence of the solution on accurate anatomical information was demonstrated by the difficulty of the technique to retrieve the subthalamic nuclei due to mismatch between the two atlases used for data simulation and recovery. Structural and functional synergy for resolution recovery (SFS-RR) improved quantification in the caudate and putamen, the main regions of interest, from -30.1% and -26.2% to -17.6% and -15.1%, respectively, for the 60 min static image and from -51.4% and -38.3% to -27.6% and -20.3% for the binding potential (BP(ND)) image, respectively. The proposed methodology proved effective in the RR of small structures from brain [¹¹C]raclopride PET images. The improvement is consistent across the anatomical variability of a simulated population as long as accurate anatomical segmentations are provided.

[Validation and optimization of the use of standardized arterial input function in N-isopropyl-p[123I]iodoamphetamine cerebral blood flow SPECT].

UNLABELLED: Use of a standardized arterial input function and calibrating it by a single blood sample has been proposed to assess quantitatively cerebral blood flow using N-isopropyl-p[123I]iodoamphetamine (IMP) and single-photon emission computed tomography. This study was intended to validate this approach using a larger number of measured arterial radioactivity curves in the clinical setting. METHOD: Arterial input function was measured for 50 patients at rest following the i.v. IMP, and its inter-subject variation was assessed. Difference between smokers and non-smokers in addition to effects of acetazolamide administration were particularly investigated. We also evaluated the accuracy of the calibration procedures by means of either a single blood sample or a continuous arterial blood withdrawal sampling for an early period. RESULTS: Inter-subject variation of the observed arterial input function appeared not to show large variations among the 50 patients, thus suggesting the validity of using the standardized arterial input function for the IMP SPECT study. There was a significant difference in the shape of the arterial input function between the smokers and non-smokers, but the calibration at an optimized sampling time provided the area-under-the curve (AUC) that was not significantly different between the two groups. The arterial input function after the acetazolamide showed no significant difference as compared with the shape at rest. The calibration of the standardized input function by means of the early integration of individual curve did not show better accuracy except for a short period of AUC (i.e., < 20 min) for longer integration period > 10 min. CONCLUSION: Thus, use of the standardized arterial input function has been validated for the IMP SPECT study. The single blood sampling procedure for calibrating the standardized input function has also been validated, and has been shown to provide better accuracy compared with the continuous withdrawal procedure.

Internal absorbed dose estimation by a TLD method for 18F-FDG and comparison with the dose estimates from whole body PET.

The thermoluminescent dosimeter (TLD) method has been proposed as a useful tool for estimating internal radiation absorbed dose in nuclear medicine. An efficient approach to verify the accuracy of the TLD method has been performed in this study. Under the standard protocol for 2-[F-18]fluoro-2-deoxy-D-glucose (18F-FDG), whole body PET experiments and simultaneous body surface dose measurements by TLDs were performed on six normal volunteers. By using the body surface dose measured with TLDs, the cumulated activities of nine source organs were estimated with a mathematical unfolding technique for three different initial guesses. The accuracy of the results obtained by the TLD method was investigated by comparison with the actual cumulated activity of the same source organs measured by whole body PET. The cumulated activities of the source organs obtained by the TLD method and whole body PET show a significant correlation (correlation coefficient, r > 0.98, level of confidence, p < 0.001) with each other. The mean effective doses in this study are 3.2 x 10(-2) mSv MBq(-1) obtained from the TLD method and 2.9 x 10(-2) mSv MBq(-1) obtained from the whole body PET. Good agreement between the results of the TLD method and whole body PET was observed.

Estimation of absorbed dose for 2-[F-18]fluoro-2-deoxy-D-glucose using whole-body positron emission tomography and magnetic resonance imaging.

The purpose of this study was to measure the cumulated activity and absorbed dose in organs after intravenous administration of 2-[F-18]fluoro-2-deoxy-D-glucose (18F-FDG) using whole-body positron emission tomography (PET) and magnetic resonance imaging (MRI). Whole-body dynamic emission scans for 18F-FDG were performed in six normal volunteers after transmission scans. The total activity of a source organ was obtained from the activity concentration of the organ measured by whole-body PET and the volume of that organ measured by whole-body T1-weighted MRI. The cumulated activity of each source organ was calculated from the time-activity curve. Absorbed doses to the individuals were estimated by the MIRD (medical internal radiation dosimetry) method using S-values adjusted to the individuals. Another calculation of cumulated activities and absorbed doses was performed using the organ volumes from the MIRD phantom and the "Japanese reference man" to investigate the discrepancy of actual individual results against the phantom results. The cumulated activities of 18 source organs were calculated, and absorbed doses of 27 target organs estimated. Among the target organs, bladder wall, brain and kidney received the highest doses for the above three sets of organ volumes. Using measured individual organ volumes, the average absorbed doses for those organs were found to be 3.1x10(-1), 3.7x10(-2) and 2.8x10(-2) mGy/MBq, respectively. The mean effective doses in this study for individuals of average body weight (64.5 kg) and the MIRD phantom of 70 kg were the same, i.e. 2.9x10(-2) mSv/MBq, while for the Japanese reference man of 60 kg the effective dose was 2.1x10(-2) mSv/MBq. The results for measured organ volumes derived from MRI were comparable to those obtained for organ volumes from the MIRD phantom. Although this study considered 18F-FDG, combined use of whole-body PET and MRI might be quite effective for improving the accuracy of estimations of the cumulated activity and absorbed dose of positron-labelled radiopharmaceuticals.